Your browser doesn't support javascript.
loading
MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.
Seguro, Fernanda S; Maciel, Felipe V R; Santos, Fernanda M; Abdo, André N R; Pereira, Thales D M; Nardinelli, Luciana; Rocha, Vanderson; Bendit, Israel.
Afiliação
  • Seguro FS; Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil; Instituto do Câncer do Estado de São Paulo, Sao Paulo, SP, Brazil. Electronic address: fernanda.seguro@hc.fm.usp.br.
  • Maciel FVR; Instituto do Câncer do Estado de São Paulo, Sao Paulo, SP, Brazil.
  • Santos FM; Instituto do Câncer do Estado de São Paulo, Sao Paulo, SP, Brazil.
  • Abdo ANR; Instituto do Câncer do Estado de São Paulo, Sao Paulo, SP, Brazil.
  • Pereira TDM; Instituto do Câncer do Estado de São Paulo, Sao Paulo, SP, Brazil.
  • Nardinelli L; Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
  • Rocha V; Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
  • Bendit I; Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Leuk Res ; 101: 106516, 2021 02.
Article em En | MEDLINE | ID: mdl-33517185
BACKGROUND: Treatment-free survival (TFS) in chronic myeloid leukemia (CML) is a new goal. This prospective study aims to evaluate imatinib discontinuation's feasibility and safety in patients with deep molecular response MR4 (BCR-ABL1 < 0.01 % IS). METHODS: Study was approved by the ethical committee and registered at Clinicaltrials.gov (NCT03239886). Incluision criteria were: age ≥ 18y, chronic phase, first-line imatinib for 36 months, MR4 for 12 months, no previous transplant or resistance. Imatinib was resumed when two samples confirmed the loss of MMR. The primary endpoint was molecular recurrence-free survival (MRFS) at 24 months. Lymphocyte subpopulations were counted in peripheral blood before discontinuation. RESULTS: 31 patients were included from Dec/2016 until Oct/2017. Median age was 54years, 58 % male, 58 % low Sokal, 65 % b3a2 transcripts, and 61 % were in MR4.5. Imatinib therapy's median time was 9.7y (3-14.9 y), median time of MR4 was 6.9y (1.6-10.3y). MRFS at 24 months was 55 % (95 % CI 39-75). Thirteen patients relapsed, 46 % after six months of discontinuation, and all patients recovered MMR. Median time to recover MMR was one month. MR4.5 was the only factor associated with MRFS. NK cells proportion at baseline was lower in patients with only MR4 who relapsed after discontinuation. CONCLUSION: With a median duration of sustained MR4 above five years, as recommended by most TKI discontinuation guidelines, the TFS was similar to previous studies. Only MR4.5 was associated with lower risk of relapse. Further studies are needed to evaluate whether patients with only MR4 and low NK cell levels are suitable for discontinuation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Leucemia Mielogênica Crônica BCR-ABL Positiva / Mesilato de Imatinib Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Aspecto: Ethics Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Leucemia Mielogênica Crônica BCR-ABL Positiva / Mesilato de Imatinib Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Aspecto: Ethics Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Ano de publicação: 2021 Tipo de documento: Article País de publicação: Reino Unido